Patritumab deruxtecan
Based on 1 publication(s) in Google Scholar
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity.
For research use only. We do not sell to patients.
- Purity: 99.08%
- CAS No.: 2227102-46-5
- Molecular Weight:155238 (average)
-
Storage:
-80°C, protect from light
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Patritumab deruxtecan
More
Biological Activity
Patritumab deruxtecan exhibits activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression[1].
Patritumab deruxtecan (0-100 nM) binds to the surface of all HER3-mutant and HER3WT MDA-MB-231 cells in a concentration-dependent manner, but does not bind to the surface of HER3EV cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2227102-46-5
-
Appearance Liquid
-
Molecular Weight 155238 (average)
-
Color Colorless to light yellow
-
SMILES
[Patritumab deruxtecan]
-
Synonyms
HER3-DXd; U3-1402
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz